These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 26093641)
1. Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. Girerd N; Collier T; Pocock S; Krum H; McMurray JJ; Swedberg K; Van Veldhuisen DJ; Vincent J; Pitt B; Zannad F Eur Heart J; 2015 Sep; 36(34):2310-7. PubMed ID: 26093641 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B; J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881 [TBL] [Abstract][Full Text] [Related]
3. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Collier TJ; Pocock SJ; McMurray JJ; Zannad F; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B Eur Heart J; 2013 Sep; 34(36):2823-9. PubMed ID: 23864130 [TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Zannad F; McMurray JJ; Drexler H; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B Eur J Heart Fail; 2010 Jun; 12(6):617-22. PubMed ID: 20388647 [TBL] [Abstract][Full Text] [Related]
5. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687 [TBL] [Abstract][Full Text] [Related]
6. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Rogers JK; McMurray JJ; Pocock SJ; Zannad F; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B Circulation; 2012 Nov; 126(19):2317-23. PubMed ID: 23042980 [TBL] [Abstract][Full Text] [Related]
7. Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms. Dhillon S Drugs; 2013 Sep; 73(13):1451-62. PubMed ID: 23881669 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF). Cannon JA; Collier TJ; Shen L; Swedberg K; Krum H; Van Veldhuisen DJ; Vincent J; Pocock SJ; Pitt B; Zannad F; McMurray JJ Eur J Heart Fail; 2015 Jul; 17(7):707-16. PubMed ID: 26139584 [TBL] [Abstract][Full Text] [Related]
9. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial. Carillo S; Zhang Y; Fay R; Angioi M; Vincent J; Sutradhor SC; Ahmed A; Pitt B; Zannad F Arch Cardiovasc Dis; 2014 Mar; 107(3):149-57. PubMed ID: 24630753 [TBL] [Abstract][Full Text] [Related]
10. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. Swedberg K; Zannad F; McMurray JJ; Krum H; van Veldhuisen DJ; Shi H; Vincent J; Pitt B; J Am Coll Cardiol; 2012 May; 59(18):1598-603. PubMed ID: 22538330 [TBL] [Abstract][Full Text] [Related]
11. Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. Chin KL; Collier TJ; Pitt B; McMurray JJ; Swedberg K; van Veldhuisen DJ; Pocock SJ; Vincent J; Turgonyi E; Zannad F; Krum H; Eur J Heart Fail; 2016 Sep; 18(9):1175-81. PubMed ID: 26833642 [TBL] [Abstract][Full Text] [Related]
12. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F; Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945 [TBL] [Abstract][Full Text] [Related]
13. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. Gheorghiade M; Khan S; Blair JE; Harinstein ME; Krum H; Mukherjee R; Pitt B; Am Heart J; 2009 Sep; 158(3):437-43. PubMed ID: 19699868 [TBL] [Abstract][Full Text] [Related]
14. Eplerenone in chronic heart failure with depressed systolic function. Volterrani M; Iellamo F Int J Cardiol; 2015 Dec; 200():12-4. PubMed ID: 26044084 [TBL] [Abstract][Full Text] [Related]
15. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF. Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796 [TBL] [Abstract][Full Text] [Related]
16. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. Olivier A; Pitt B; Girerd N; Lamiral Z; Machu JL; McMurray JJV; Swedberg K; van Veldhuisen DJ; Collier TJ; Pocock SJ; Rossignol P; Zannad F; Pizard A Eur J Heart Fail; 2017 Sep; 19(9):1186-1197. PubMed ID: 28303624 [TBL] [Abstract][Full Text] [Related]
17. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. Gheorghiade M; Böhm M; Greene SJ; Fonarow GC; Lewis EF; Zannad F; Solomon SD; Baschiera F; Botha J; Hua TA; Gimpelewicz CR; Jaumont X; Lesogor A; Maggioni AP; JAMA; 2013 Mar; 309(11):1125-35. PubMed ID: 23478743 [TBL] [Abstract][Full Text] [Related]
18. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767 [TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of eplerenone in patients with chronic heart failure. Ademi Z; Pasupathi K; Krum H; Liew D Am J Cardiovasc Drugs; 2014 Jun; 14(3):209-16. PubMed ID: 24610254 [TBL] [Abstract][Full Text] [Related]
20. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. Pitt B; White H; Nicolau J; Martinez F; Gheorghiade M; Aschermann M; van Veldhuisen DJ; Zannad F; Krum H; Mukherjee R; Vincent J; J Am Coll Cardiol; 2005 Aug; 46(3):425-31. PubMed ID: 16053953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]